Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- SiRNA Screening in 37 KRAS Mutant colorectal cancer cell lines identified RAF1 and MEK Inhibition as synergistic, whereas MEK Inhibition alone led to quick resistance via upregulation of RAF-signalling. This finding could be reproduced in colorectal and lung cancer cell lines in a second, independent screen.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/988
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- B-Raf/VEGFR-2 Inhibitor RAF265,Selumetinib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25199829
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| B-Raf/VEGFR-2 Inhibitor RAF265 | Sensitivity | true |
| Selumetinib | Sensitivity | true |